The ability of AMG 133 to lower body weight and improve metabolic markers in male obese mice and cynomolgus monkeys is reported by researchers, who also confirm the GIP receptor antagonist and GLP- 1 receptor agonist activities in cell-based systems
To mitigate this drawback, the pharmacological administration of GIP, primarily known for its insulinotropic and mild appetite-suppressing properties [7], is also suggested to have an anti-emetic effect, potentially allowing GIP co-agonism to increase tolerability to the GLP-1 component [8]
[DOI] [PMC free article] [PubMed] [Google Scholar] 66.Ping M.-H
What is Beacon Research Solutions
This is not a failure of willpower
By attending, you are not only expanding your clinical expertise but directly supporting NCOS's mission to advance evidence-based obesity care through education, advocacy, and research across the state